Product Description
Mechanisms of Action: EGFR Inhibitor, HER2 Inhibitor, VEGFR Inhibitor, TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Kidney Diseases, Cystic|Non-Small-Cell Lung Cancer|Polycystic Kidney, Autosomal Dominant|Polycystic Kidney Diseases|Breast Cancer|Brain Cancer|Meningeal Carcinomatosis|Glioblastoma|Meningeal Cancer|Arthrogryposis
Phase 1: Oncology Solid Tumor Unspecified|Kidney Diseases, Cystic|Polycystic Kidney, Autosomal Recessive|Polycystic Kidney Diseases|Non-Small-Cell Lung Cancer|Breast Cancer|Gastrointestinal Cancer|Esophageal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03096080 |
KD019-103 | P1 |
Completed |
Kidney Diseases, Cystic|Polycystic Kidney, Autosomal Recessive|Polycystic Kidney Diseases |
2019-09-30 |
12% |
2022-05-12 |
Primary Endpoints|Start Date|Treatments |
NCT02205463 |
s14-01171 | P1 |
Withdrawn |
Esophageal Cancer|Gastrointestinal Cancer |
2017-07-01 |
2019-05-25 |
Treatments |
|
NCT00336765 |
XL647-002 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-08-01 |
2019-03-21 |
Treatments |
|
NCT00704392 |
XL647-003 | P1 |
Withdrawn |
Non-Small-Cell Lung Cancer|Breast Cancer |
2009-12-01 |
2019-03-18 |
Treatments |
|
NCT00086528 |
XL647-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2007-07-01 |
2019-03-21 |
Treatments |
|
NCT03203642 |
ACT17675 | P2 |
Completed |
Arthrogryposis|Kidney Diseases, Cystic|Polycystic Kidney, Autosomal Dominant|Polycystic Kidney Diseases |
2022-01-25 |
55% |
2023-02-07 |
Primary Endpoints |
NCT02844439 |
KD019-208 | P2 |
Completed |
Glioblastoma|Brain Cancer |
2020-04-30 |
50% |
2021-09-23 |
|
NCT01559363 |
KD019-101 | P2 |
Completed |
Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant|Arthrogryposis|Kidney Diseases, Cystic |
2019-02-08 |
37% |
2022-11-09 |
|
NCT02616393 |
KD019-206 | P2 |
Completed |
Brain Cancer|Meningeal Cancer|Meningeal Carcinomatosis|Non-Small-Cell Lung Cancer |
2018-04-03 |
50% |
2022-03-17 |
|
NCT02616055 |
KD019-207 | P2 |
Terminated |
Kidney Diseases, Cystic|Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant |
2016-12-21 |
2022-05-27 |
Primary Endpoints|Start Date|Treatments |
|
NCT02154529 |
KD019-204 | P2 |
Terminated |
Breast Cancer|Brain Cancer |
2015-09-13 |
2022-04-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT00364780 |
XL647-201 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2010-05-01 |
2019-03-21 |
Treatments |
|
NCT00522145 |
XL647-203 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2009-10-01 |
2019-03-21 |
Treatments |
|
NCT01487174 |
KD019-301 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-07-25 |
2025-08-27 |
Primary Endpoints|Treatments |